You may have seen recent reports about the decision to not recommend a life-extending drug called Enhertu (Trastuzumab Deruxtecan) for the treatment of breast cancer on the NHS. Following ongoing commercial discussions between NICE, the NHS and the drug manufacturer, …
The government has published its full response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK. The response outlines plans to make the UK one of the best places in the world to conduct clinical trials …
Updated on 20 November The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has been agreed by the government, NHS England, and the Association of the British Pharmaceutical Industry (ABPI) and will run for 5 years until 31 …
Recent Comments